UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 408

Sortiert nach

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

The New England journal of medicine, 2019-03, Vol.380 (10), p.981-983

2019

Volltextzugriff (PDF)

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

2014

Volltextzugriff (PDF)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet (British edition), 2019-08, Vol.394 (10198), p.576-586

2019

Volltextzugriff (PDF)

Trial of Spesolimab for Generalized Pustular Psoriasis

The New England journal of medicine, 2021-12, Vol.385 (26), p.2431-2440

2021

Volltextzugriff (PDF)

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Therapeutic Advances in Musculoskeletal Disease, 2017-11, Vol.9 (11), p.277-294

2017

Volltextzugriff (PDF)

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan

Journal of dermatological science, 2011-07, Vol.63 (1), p.40-46

2011

Volltextzugriff (PDF)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.400-409

2015

Volltextzugriff (PDF)

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Experimental dermatology, 2023-07, Vol.32 (7), p.1048-1050

2023

Volltextzugriff (PDF)

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Journal of the American Academy of Dermatology, 2017-01, Vol.76 (1), p.60-69.e9

2017

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Burden of atopic dermatitis in Asia

Journal of dermatology, 2019-10, Vol.46 (10), p.825-834

2019

Volltextzugriff (PDF)

Elderly‐onset generalized pustular psoriasis: a case series

Clinical and experimental dermatology, 2022-08, Vol.47 (8), p.1567-1570

2022

Volltextzugriff (PDF)

Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature

Lupus, 2022-06, Vol.31 (7), p.891-894

2022

Volltextzugriff (PDF)

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study

Journal of dermatology, 2023-02, Vol.50 (2), p.183-194

2023

Volltextzugriff (PDF)

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work

Journal of dermatology, 2018-11, Vol.45 (11), p.1353-1356

2018

Volltextzugriff (PDF)

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

The Lancet (British edition), 2023-10, Vol.402 (10412), p.1541-1551

2023

Volltextzugriff (PDF)

Response to “a case of acquired idiopathic generalized anhidrosis following severe acute respiratory syndrome coronavirus 2 vaccination”

Journal of dermatology, 2024-01, Vol.51 (1), p.e22-e23

2024

Volltextzugriff (PDF)

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

International journal of molecular sciences, 2022-05, Vol.23 (10), p.5518

2022

Volltextzugriff (PDF)

Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?

Experimental dermatology, 2024-03, Vol.33 (3), p.e15056-n/a

2024

Volltextzugriff (PDF)

Deficiency of interleukin‐36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan

Experimental dermatology, 2023-08, Vol.32 (8), p.1272-1278

2023

Volltextzugriff (PDF)

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan

Journal of dermatology, 2020-09, Vol.47 (9), p.1046-1049

2020

Volltextzugriff (PDF)

Acquired idiopathic generalized anhidrosis diagnosed following mRNA COVID‐19 vaccination—A case series

Australasian journal of dermatology, 2023-02, Vol.64 (1), p.e76-e79

2023

Volltextzugriff (PDF)

Report of a case with CARD14‐associated papulosquamous eruptions and multiple skin cancers

Photodermatology, photoimmunology & photomedicine, 2024-05, Vol.40 (3), p.e12969-n/a

2024

Volltextzugriff (PDF)

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Experimental dermatology, 2023-12, Vol.32 (12), p.2138-2148

2023

Volltextzugriff (PDF)

Psoriasis and Co-morbidity

Acta dermato-venereologica, 2020-01, Vol.100 (3), p.adv00033-87

2020

Volltextzugriff (PDF)

1 – 25 von 408

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(370)
Mit Volltextzugriff
(306)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Trial of Spesolimab for Generalized Pustular Psoriasis

Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Burden of atopic dermatitis in Asia

Elderly‐onset generalized pustular psoriasis: a case series

Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Response to “a case of acquired idiopathic generalized anhidrosis following severe acute respiratory syndrome coronavirus 2 vaccination”

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?

Deficiency of interleukin‐36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan

Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: A retrospective analysis of 66 cases in a single center in Taiwan

Acquired idiopathic generalized anhidrosis diagnosed following mRNA COVID‐19 vaccination—A case series

Report of a case with CARD14‐associated papulosquamous eruptions and multiple skin cancers

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Psoriasis and Co-morbidity

Suchergebnisse filtern